Home › Products › Gene function › Viral transduction › Lentivirus › Vector systems › Constitutive promoter

Lentivirus

Lentiviral vector systems for constitutive gene expression

Lentiviral vectors with CMV or EF1 alpha promoters for constitutive gene expression

These lentiviral expression systems are designed for constitutive gene expression from either a CMV or EF1-alpha promoter.

Biscistronic options

The IRES Vectors included with the bicistronic lentiviral expression systems each contain a multiple cloning site located upstream of the IRES from which a selection marker is expressed. Because your gene of interest and a selection marker are translated from a single RNA, you can be certain that nearly 100% of the colonies that are resistant to puromycin, hygromycin, and G418 also express your protein of interest.

Fluorescent protein options

For lentiviral vectors that express fluorescent protein tags and markers, including the bicistronic pLVX-IRES-ZsGreen1 and pLVX-IRES-mCherry vectors, see our Fluorescent Lentiviral Expression Vectors webpage.

EF1-alpha promoter versions

Lenti-X lentiviral vector systems with EF1-alpha promoters allow you to achieve robust, constitutive, long-term expression of your gene of interest in cell types in which CMV promoters are often silenced, such as hematopoietic and stem cells.

Lentiviral packaging system included

Many of our lentiviral systems are complete systems that include our high-titer Lenti-X Packaging Single Shots (VSV-G) when used with the Lenti-X 293T Cell Line (not included), generates titers that are far superior to those of other commercially available lentiviral packaging systems. Frequently, an entire dish of target cells can be effectively transduced using just 10–100 µl of unconcentrated viral supernatant.

More Less

Cat. #

Product

Size

Price

License

Quantity

Details

632182

Lenti-X™ Bicistronic Expression System (Hyg)

Each

$1096.00

License Statement

ID Number
63	Use of this product is covered by one or more of the following U.S. Patent Nos. and corresponding patent claims outside the U.S.: 6,998,115; 7,427,394. This product is intended for research purposes only. It may not be used for (i) any human or veterinary use, including without limitation therapeutic and prophylactic use, (ii) any clinical use, including without limitation diagnostic use, (iii) screening of chemical and/or biological compounds for the identification of pharmaceutically active agents (including but not limited to screening of small molecules), target validation, preclinical testing services, or drug development. Any use of this product for any of the above mentioned purposes requires a license from the Massachusetts Institute of Technology.
55	cPPT Element. This product and its use are the subject to one or more of the following U.S. Pat. Nos. 6,682,907, 7,981,671, 8,093,042, 8,367,068, 8,460,678, 8,512,994 and foreign equivalents. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot disclose information, sell or otherwise transfer this product, its components or materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for any commercial purposes. If the buyer is not willing to accept the limitations of this limited use statement, Takara Bio USA, Inc. is willing to accept return of the product with a full refund. For information on purchasing a license to the DNA-Flap technology for purposes other than research, contact the Transfer of Technology Office, Institut Pasteur, 28 rue du Docteur Roux, 75 724 Paris Cedex 15 (www.pasteur.fr).
47	Portions of this product are covered by several patent applications owned by, or licensed to, GE Healthcare Dharmacon Inc. The purchase of this product conveys to the buyer the limited, non-exclusive, non-transferable right (without the right to resell, repackage, or further sublicense) under these patent rights to perform the viral infection methods using the lentiviral vectors claimed in those patent applications for research purposes solely in conjunction with this product. No other license is granted to the buyer whether expressly, by implication, by estoppel or otherwise. In particular, the purchase of this product does not include nor carry any right or license to use, develop, or otherwise exploit this product commercially, and no other rights are conveyed to the buyer to use the product or components of the product for any other purposes, including without limitation, provision of services to a third party, generation of commercial databases, or clinical diagnostics or therapeutics. This product is sold pursuant to a license from GE Healthcare Dharmacon Inc, and GE Healthcare Dharmacon Inc., reserves all other rights under these patent rights. For information on purchasing a license to the patent rights for uses other than in conjunction with this product or to use this product for purposes other than research, please contact GE Healthcare Dharmacon Inc., LSlicensing @ge.com.
89	This product is protected by U.S. Patent 9,945,850 and additional pending patent. For further license information, please contact a Takara Bio USA licensing representative by email at licensing@takarabio.com.

The Lenti-X Bicistronic Expression Systems enable you to produce high-titer recombinant lentivirus for the purpose of transferring genes into dividing or non-dividing mammalian cells. The pLVX-IRES-Neo Vector contains an internal ribosome entry site (IRES) followed by a drug resistance marker, so that your gene of interest and hygromycin resistance are simultaneously coexpressed from a single mRNA transcript. The Lenti-X packaging system is a proprietary combination of plasmids that collectively expresses all the viral proteins necessary for assembling the vector into infectious virions. Lenti-X Packaging Single Shots, which contain lyophilized packaging plasmids and transfection reagent, are used for efficient introduction of the Lenti-X packaging mix and the pLVX-IRES-Hyg Vector into Lenti-X 293T Cells (Cat. No. 632180; not included) to produce lentivirus. Tet Approved FBS is supplied to ensure the maximal activity of tetracycline-responsive promoters that are used to express high levels of specific packaging mix proteins. The combined activities of these optimized reagents allows the transfected Lenti-X 293T cultures to produce high titers of VSV-G pseudotyped lentivirus that is both safe and replication-incompetent, and able to transduce virtually any cell type. The Lenti-X GoStix can be used to determine whether virus production is within a usable range or for selecting the best time to harvest your virus. The system provides enough reagents for 16 packaging reactions.

Notice to purchaser

Our products are to be used for Research Use Only. They may not be used for any other purpose, including, but not limited to, use in humans, therapeutic or diagnostic use, or commercial use of any kind. Our products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without our prior written approval.

Components

632181

Lenti-X™ Bicistronic Expression System (Neo)

Each

$1096.00

License Statement

ID Number
63	Use of this product is covered by one or more of the following U.S. Patent Nos. and corresponding patent claims outside the U.S.: 6,998,115; 7,427,394. This product is intended for research purposes only. It may not be used for (i) any human or veterinary use, including without limitation therapeutic and prophylactic use, (ii) any clinical use, including without limitation diagnostic use, (iii) screening of chemical and/or biological compounds for the identification of pharmaceutically active agents (including but not limited to screening of small molecules), target validation, preclinical testing services, or drug development. Any use of this product for any of the above mentioned purposes requires a license from the Massachusetts Institute of Technology.
55	cPPT Element. This product and its use are the subject to one or more of the following U.S. Pat. Nos. 6,682,907, 7,981,671, 8,093,042, 8,367,068, 8,460,678, 8,512,994 and foreign equivalents. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot disclose information, sell or otherwise transfer this product, its components or materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for any commercial purposes. If the buyer is not willing to accept the limitations of this limited use statement, Takara Bio USA, Inc. is willing to accept return of the product with a full refund. For information on purchasing a license to the DNA-Flap technology for purposes other than research, contact the Transfer of Technology Office, Institut Pasteur, 28 rue du Docteur Roux, 75 724 Paris Cedex 15 (www.pasteur.fr).
47	Portions of this product are covered by several patent applications owned by, or licensed to, GE Healthcare Dharmacon Inc. The purchase of this product conveys to the buyer the limited, non-exclusive, non-transferable right (without the right to resell, repackage, or further sublicense) under these patent rights to perform the viral infection methods using the lentiviral vectors claimed in those patent applications for research purposes solely in conjunction with this product. No other license is granted to the buyer whether expressly, by implication, by estoppel or otherwise. In particular, the purchase of this product does not include nor carry any right or license to use, develop, or otherwise exploit this product commercially, and no other rights are conveyed to the buyer to use the product or components of the product for any other purposes, including without limitation, provision of services to a third party, generation of commercial databases, or clinical diagnostics or therapeutics. This product is sold pursuant to a license from GE Healthcare Dharmacon Inc, and GE Healthcare Dharmacon Inc., reserves all other rights under these patent rights. For information on purchasing a license to the patent rights for uses other than in conjunction with this product or to use this product for purposes other than research, please contact GE Healthcare Dharmacon Inc., LSlicensing @ge.com.
89	This product is protected by U.S. Patent 9,945,850 and additional pending patent. For further license information, please contact a Takara Bio USA licensing representative by email at licensing@takarabio.com.

The Lenti-X Bicistronic Expression Systems enable you to produce high-titer recombinant lentivirus for the purpose of transferring genes into dividing or non-dividing mammalian cells. The pLVX-IRES-Neo Vector contains an internal ribosome entry site (IRES) followed by a drug resistance marker, so that your gene of interest and G418 resistance are simultaneously coexpressed from a single mRNA transcript. The Lenti-X packaging system is a proprietary combination of plasmids that collectively expresses all the viral proteins necessary for assembling the vector into infectious virions. Lenti-X Packaging Single Shots, which contain lyophilized packaging plasmids and transfection reagent, are used for efficient introduction of the Lenti-X packaging mix and the pLVX-IRES-Neo Vector into Lenti-X 293T Cells (Cat. No. 632180; not included) to produce lentivirus. Tet Approved FBS is supplied to ensure the maximal activity of tetracycline-responsive promoters that are used to express high levels of specific packaging mix proteins. The combined activities of these optimized reagents allows the transfected Lenti-X 293T cultures to produce high titers of VSV-G-pseudotyped lentivirus that is both safe and replication-incompetent, and able to transduce virtually any cell type. The Lenti-X GoStixcan be used to determine whether virus production is within a usable range or for selecting the best time to harvest your virus. The system provides enough reagents for 16 packaging reactions.

Notice to purchaser

Components

632183

Lenti-X™ Bicistronic Expression System (Puro)

Each

$1096.00

License Statement

ID Number
63	Use of this product is covered by one or more of the following U.S. Patent Nos. and corresponding patent claims outside the U.S.: 6,998,115; 7,427,394. This product is intended for research purposes only. It may not be used for (i) any human or veterinary use, including without limitation therapeutic and prophylactic use, (ii) any clinical use, including without limitation diagnostic use, (iii) screening of chemical and/or biological compounds for the identification of pharmaceutically active agents (including but not limited to screening of small molecules), target validation, preclinical testing services, or drug development. Any use of this product for any of the above mentioned purposes requires a license from the Massachusetts Institute of Technology.
55	cPPT Element. This product and its use are the subject to one or more of the following U.S. Pat. Nos. 6,682,907, 7,981,671, 8,093,042, 8,367,068, 8,460,678, 8,512,994 and foreign equivalents. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot disclose information, sell or otherwise transfer this product, its components or materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for any commercial purposes. If the buyer is not willing to accept the limitations of this limited use statement, Takara Bio USA, Inc. is willing to accept return of the product with a full refund. For information on purchasing a license to the DNA-Flap technology for purposes other than research, contact the Transfer of Technology Office, Institut Pasteur, 28 rue du Docteur Roux, 75 724 Paris Cedex 15 (www.pasteur.fr).
47	Portions of this product are covered by several patent applications owned by, or licensed to, GE Healthcare Dharmacon Inc. The purchase of this product conveys to the buyer the limited, non-exclusive, non-transferable right (without the right to resell, repackage, or further sublicense) under these patent rights to perform the viral infection methods using the lentiviral vectors claimed in those patent applications for research purposes solely in conjunction with this product. No other license is granted to the buyer whether expressly, by implication, by estoppel or otherwise. In particular, the purchase of this product does not include nor carry any right or license to use, develop, or otherwise exploit this product commercially, and no other rights are conveyed to the buyer to use the product or components of the product for any other purposes, including without limitation, provision of services to a third party, generation of commercial databases, or clinical diagnostics or therapeutics. This product is sold pursuant to a license from GE Healthcare Dharmacon Inc, and GE Healthcare Dharmacon Inc., reserves all other rights under these patent rights. For information on purchasing a license to the patent rights for uses other than in conjunction with this product or to use this product for purposes other than research, please contact GE Healthcare Dharmacon Inc., LSlicensing @ge.com.
89	This product is protected by U.S. Patent 9,945,850 and additional pending patent. For further license information, please contact a Takara Bio USA licensing representative by email at licensing@takarabio.com.

The Lenti-X Bicistronic Expression Systems enable you to produce high-titer recombinant lentivirus for the purpose of transferring genes into dividing or non-dividing mammalian cells. The pLVX-IRES-Puro Vector contains an internal ribosome entry site (IRES) followed by a drug resistance marker, so that your gene of interest and puromycin resistance are simultaneously coexpressed from a single mRNA transcript. The Lenti-X packaging system is a proprietary combination of plasmids that collectively expresses all the viral proteins necessary for assembling the vector into infectious virions. Lenti-X Packaging Single Shots, which contain lyophilized Lenti-X packaging plasmids and transfection reagent, are used for efficient introduction of the packaging plasmids and the pLVX-IRES-Puro Vector into Lenti-X 293T Cells (Cat. No. 632180; not included) to produce lentivirus. These optimized reagents allow the transfected Lenti-X 293T cultures to produce high titers of VSV-G pseudotyped lentivirus that is both safe and replication-incompetent, and able to transduce virtually any cell type. The Lenti-X GoStixcan be used to determine whether virus production is within a usable range or for selecting the best time to harvest your virus. The system provides enough reagents for 16 packaging reactions.

Notice to purchaser

Components

632164

Lenti-X™ Expression System

Each

$1096.00

License Statement

ID Number
63	Use of this product is covered by one or more of the following U.S. Patent Nos. and corresponding patent claims outside the U.S.: 6,998,115; 7,427,394. This product is intended for research purposes only. It may not be used for (i) any human or veterinary use, including without limitation therapeutic and prophylactic use, (ii) any clinical use, including without limitation diagnostic use, (iii) screening of chemical and/or biological compounds for the identification of pharmaceutically active agents (including but not limited to screening of small molecules), target validation, preclinical testing services, or drug development. Any use of this product for any of the above mentioned purposes requires a license from the Massachusetts Institute of Technology.
55	cPPT Element. This product and its use are the subject to one or more of the following U.S. Pat. Nos. 6,682,907, 7,981,671, 8,093,042, 8,367,068, 8,460,678, 8,512,994 and foreign equivalents. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot disclose information, sell or otherwise transfer this product, its components or materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for any commercial purposes. If the buyer is not willing to accept the limitations of this limited use statement, Takara Bio USA, Inc. is willing to accept return of the product with a full refund. For information on purchasing a license to the DNA-Flap technology for purposes other than research, contact the Transfer of Technology Office, Institut Pasteur, 28 rue du Docteur Roux, 75 724 Paris Cedex 15 (www.pasteur.fr).
47	Portions of this product are covered by several patent applications owned by, or licensed to, GE Healthcare Dharmacon Inc. The purchase of this product conveys to the buyer the limited, non-exclusive, non-transferable right (without the right to resell, repackage, or further sublicense) under these patent rights to perform the viral infection methods using the lentiviral vectors claimed in those patent applications for research purposes solely in conjunction with this product. No other license is granted to the buyer whether expressly, by implication, by estoppel or otherwise. In particular, the purchase of this product does not include nor carry any right or license to use, develop, or otherwise exploit this product commercially, and no other rights are conveyed to the buyer to use the product or components of the product for any other purposes, including without limitation, provision of services to a third party, generation of commercial databases, or clinical diagnostics or therapeutics. This product is sold pursuant to a license from GE Healthcare Dharmacon Inc, and GE Healthcare Dharmacon Inc., reserves all other rights under these patent rights. For information on purchasing a license to the patent rights for uses other than in conjunction with this product or to use this product for purposes other than research, please contact GE Healthcare Dharmacon Inc., LSlicensing @ge.com.
89	This product is protected by U.S. Patent 9,945,850 and additional pending patent. For further license information, please contact a Takara Bio USA licensing representative by email at licensing@takarabio.com.

The Lenti-X Expression System enables you to produce exceptionally high titers of recombinant lentivirus for expression of any cDNA in any cell type susceptible to lentivirus transduction. The Lenti-X packaging system is a proprietary combination of plasmids that collectively expresses all the viral proteins necessary for high-efficiency packaging of lentiviral vector transcripts into infectious lentivirus particles. Lenti-X Packaging Single Shots, which contain lyophilized Lenti-X packaging plasmids and transfection reagent, are used for efficient introduction of the packaging mix and the pLVX-Puro Vector into 293T cells with very high efficiency. The concerted effects of these components allow 293T cells to produce high-titer replication incompetent lentiviral supernatants for a safe transduction of virtually any cell type. The Lenti-X GoStix can be used to determine whether virus production is within a usable range or for selecting the best time to harvest your virus. The system provides enough reagents for 16 packaging reactions.

Notice to purchaser

Components

631253

Lenti-X™ Expression System (EF1alpha Version)

Each

$1096.00

License Statement

ID Number
47	Portions of this product are covered by several patent applications owned by, or licensed to, GE Healthcare Dharmacon Inc. The purchase of this product conveys to the buyer the limited, non-exclusive, non-transferable right (without the right to resell, repackage, or further sublicense) under these patent rights to perform the viral infection methods using the lentiviral vectors claimed in those patent applications for research purposes solely in conjunction with this product. No other license is granted to the buyer whether expressly, by implication, by estoppel or otherwise. In particular, the purchase of this product does not include nor carry any right or license to use, develop, or otherwise exploit this product commercially, and no other rights are conveyed to the buyer to use the product or components of the product for any other purposes, including without limitation, provision of services to a third party, generation of commercial databases, or clinical diagnostics or therapeutics. This product is sold pursuant to a license from GE Healthcare Dharmacon Inc, and GE Healthcare Dharmacon Inc., reserves all other rights under these patent rights. For information on purchasing a license to the patent rights for uses other than in conjunction with this product or to use this product for purposes other than research, please contact GE Healthcare Dharmacon Inc., LSlicensing @ge.com.
63	Use of this product is covered by one or more of the following U.S. Patent Nos. and corresponding patent claims outside the U.S.: 6,998,115; 7,427,394. This product is intended for research purposes only. It may not be used for (i) any human or veterinary use, including without limitation therapeutic and prophylactic use, (ii) any clinical use, including without limitation diagnostic use, (iii) screening of chemical and/or biological compounds for the identification of pharmaceutically active agents (including but not limited to screening of small molecules), target validation, preclinical testing services, or drug development. Any use of this product for any of the above mentioned purposes requires a license from the Massachusetts Institute of Technology.
55	cPPT Element. This product and its use are the subject to one or more of the following U.S. Pat. Nos. 6,682,907, 7,981,671, 8,093,042, 8,367,068, 8,460,678, 8,512,994 and foreign equivalents. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot disclose information, sell or otherwise transfer this product, its components or materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for any commercial purposes. If the buyer is not willing to accept the limitations of this limited use statement, Takara Bio USA, Inc. is willing to accept return of the product with a full refund. For information on purchasing a license to the DNA-Flap technology for purposes other than research, contact the Transfer of Technology Office, Institut Pasteur, 28 rue du Docteur Roux, 75 724 Paris Cedex 15 (www.pasteur.fr).
89	This product is protected by U.S. Patent 9,945,850 and additional pending patent. For further license information, please contact a Takara Bio USA licensing representative by email at licensing@takarabio.com.

The Lenti-X Expression System (EF1α Version) enables you to produce exceptionally high titers of recombinant lentivirus for expression of any cDNA in any cell type susceptible to lentiviral transduction. The System contains an HIV-1-based, lentiviral expression vector, pLVX-EF1α-IRES-Puro, designed to constitutively express a protein of interest and puromycin resistance (Puro^r). Constitutive expression of these proteins is driven by the human elongation factor 1 alpha (EF1α) promoter, which allows protein expression in mammalian cells in which the CMV promoter is silenced. The System also includes Lenti-X Packaging Single Shots (VSV-G) and Lenti-X GoStix.

Notice to purchaser

Components

Overview

Complete systems include a high-titer lentiviral packaging system and an optimized transfer vector
Vector design optimized for high expression and high titers
- cPPT element enhances transduction efficiency
- WPRE enhances expression of your transgene and increases viral titer
EF1-alpha promoter versions for cell types where CMV promoter may be silenced
IRES-containing bicistronic vectors allow the simultaneous expression of your gene and a drug selection marker from the same RNA transcript

More Information

Please see the product's Certificate of Analysis for information about storage conditions, product components, and technical specifications. Please see the Kit Components List to determine kit components. Certificates of Analysis and Kit Components Lists are located under the Documents tab.

Choose the right lentiviral product for your research

Lentiviral product selection guide

Takara Bio offers a broad range of research tools for gene delivery using lentiviral vectors, including a selection of vector systems, packaging mixes, and titration kits. Use our selection guide for a brief description of the products and links to further information.

Lentiviral products guide Learning center

Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2019 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.

Lentiviral vector systems for constitutive gene expression

Biscistronic options

Fluorescent protein options

EF1-alpha promoter versions

Lentiviral packaging system included

Notice to purchaser

Lentiviral vector design

High-titer lentivirus production

Notice to purchaser

High-titer lentivirus production

Notice to purchaser

Lentiviral vector design

4th generation lentiviral packaging system

High-titer lentivirus production

Notice to purchaser

Lentiviral vector design

4th generation lentiviral packaging system

High-titer lentivirus production

Notice to purchaser

4th generation lentiviral packaging system

Lentiviral vector systems with EF-1 alpha promoters

Overview

More Information